“Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs industry and market set to grow to $23bn by 2024” says Visiongain report

31 July 2019
Pharma

Visiongain has launched a new pharma report Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne.

The sector has obvious growth potential, since the majority of the AMD and DR patient population currently still lack any treatment options. This means that there are vast patient populations for manufacturers to target with new AMD and DR products, and new candidates in these areas can hope for fast track status from regulatory bodies.

The lead analyst of the report commented "Another question-mark that hangs over the future of the AMD and DR pharmaceuticals sector is the widespread belief that the best cure for these conditions is not biological or small-molecule drug interventions that can stabilise or reverse disease progression, but rather prevention: a therapeutic approach that can stop AMD and DR developing in the first place is widely seen as the major goal by scientists and clinicians working in the field."

Leading companies featured in the report include Acucela, Inc., Allergan Plc, Bayer AG, F. Hoffman-La Roche, Ltd., GlaxoSmithKline Pharmaceuticals, Ltd., Novartis AG, Pfizer, Inc., Valent Pharmaceuticals International, Plc and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Biological Drug API Manufacturing market set to grow to $11bn by 2025” says Visiongain report

Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes.

07 November 2019

Read

“global radiation oncology market is anticipated to surpass USD 6.5 billion by 2020”, says Visiongain

Growing aging population, urbanization, and growing wealth in low- and middle-income countries such as China and India are anticipated to boost the APAC radiation oncology market.

07 November 2019

Read

“Global Rabies Diagnostics Market is anticipated to surpass USD 1.8 billion by 2020”, says Visiongain

Several international healthcare organizations are working with healthcare organizations to develop and market new detection assays to drive efforts aimed at fighting the disease.

07 November 2019

Read

“Global spinal muscular atrophy (SMA) market is anticipated is to surpass USD 950 Million by 2020”, says Visiongain

Increasing awareness of SMA and increasing numbers of programs to expand treatment options for rare diseases are key factors that are boosting the market growth.

07 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever